10.1002/JLCR.1676
The research focuses on the carbon-14 radiosynthesis of combretastatin A-1 (CA1) and its phosphate prodrug CA1P, which are derived from the African bush willow tree and have significant medicinal value due to their ability to inhibit tubulin assembly and act as vascular disrupting agents in cancer treatment. The study details a four-step synthesis process to incorporate carbon-14 into CA1 and CA1P with high specific activity. Key reactants include the CA1 precursor, [14C]methyl iodide for radiolabeling, TiCl4 for deprotection, and dibenzyl phosphite for phosphorylation. The methodology involves methylation of the C-4 protected phenolic moiety, de-isopropylation with TiCl4, and conversion to the phosphate prodrug. Analyses were performed using 1H NMR, analytical HPLC, and radio-TLC to ensure chemical and radiochemical purities, with the final product achieving a specific activity of 55 mCi/mmol.